Original Research

Prevalence and Impact of COVID-19 in Immuno-compromised Individuals: An Experience from a Private Outpatient Setting of South Punjab, Pakistan

DOI https://doi.org/10.70302/jpsim.v3i2.2222
Received: 07 Jan 2022 Accepted: 16 Apr 2022 Published Online: 15 Jun 2022

Abstract

Objective

To find out the prevalence and impact of COVID-19 on immunocompromised patients visiting outpatient department of a private healthcare facility of South Punjab, Pakistan.

Methods

This cross-sectional study was done at Outpatient Department of Aleena Hospital, Bahawalpur, Pakistan from 1st June 2020 to 30th December 2020. We included a total of 197 patients of both genders aged between 15 to 90 years visiting outpatient department of Aleena Hospital for various medical reasons. All patients underwent antibody testing for COVID-19 adopting immunochromatography for both IgG and IgM. A patient was labeled as immunocompromised if having diabetes mellitus or liver cirrhosis.

Results

In a total of 197 patients, 122 (61.9%) were male. Overall, mean age was 45.1±13.3 years ranging 15 to 90 years. A total of 50 (25.4%) cases were antibody positive for COVID-19. BMI ≥ 25 (p=0.045), and “been to close proximity with someone who travelled outside/inside the country” (p=0.014) were noted to have significant association with COVID-19 positive cases while all other variables had insignificant association (p>0.05). Presence of diabetes mellitus was noted to have significant association with COVID-19 antibody positivity (p=0.002). Overall, no significant association of immunocompromised status and COVID-19 antibodies positivity was observed (p=0.090).

Conclusion

Prevalence of positive COVID-19 antibodies was very high among patients visiting outpatient department of a private healthcare setting of South Punjab, Pakistan. Immunocompromised individuals were not found to have any significant association with COVID-19 infections.

Keywords
COVID-19 diabetes mellitus immunocompromised polymerase chain reaction.

How to Cite This Article

Ali QM, Imran A, Shafique S, Khan R, Ullah HMK, Sohail S, et al.. Prevalence and Impact of COVID-19 in Immuno-compromised Individuals: An Experience from a Private Outpatient Setting of South Punjab, Pakistan. J Pak Soc Intern Med. 2022;3(2):117–120. doi:10.70302/jpsim.v3i2.2222

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. Organization W.H. WHO Coronavirus disease (COVID-19) dashboard. [Updated 2020, cited 2022] Available from: [https://covid19.who.int/]
  2. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99(9):47-56.
  3. Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Clin Infect Dis. 2020;71(16):2199-206.
  4. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: Current state of the science. Immunity. 2020;52(6):910-41.
  5. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768.
  6. Anirvan P, Bharali P, Gogoi M, Thuluvath PJ, Singh SP, Satapathy SK. Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome - what we know so far. World J Hepatol. 2020;12(12):1182-97.
  7. Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martinez-Colon GJ, McKechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070-6.
  8. Urra JM, Cabrera CM, Porras L, Ródenas I. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol. 2020; doi:10.1016/j.clim.2020.108486 doi:10.1016/j.clim.2020.108486
  9. Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021;9(6):e002630.
  10. Ahmed O, Asghar M, Khurshaidi M, Yasmin F, Kanwal N, Khokher AJ, et al. Provision of surgical services to COVID-19-infected patients at a tertiary care center in Pakistan: A one-year clinical review of the year 2020 in general surgery department. Cureus. 2021;13(1): e12705.
  11. Vaid N, Ardissino M, Reed TA, Goodall J, Utting P, Miscampbell M, et al. Clinical characteristics and outcomes of immunosuppressed patients hospitalized with COVID-19: experience from London. J Intern Med. 2021;289(3):385-94.
  12. Baek MS, Lee MT, Kim WY, Choi JC, Jung SY. COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea. PLoS One. 2021;16(10): e025764.
  13. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020; doi: 10.1136/bmj.m3249 doi:10.1136/bmj.m3249
  14. Ferrari A, Zecca M, Rizzari C, Porta F, Provenzi M, Marinoni M, et al. Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy. Pediatr Blood Cancer. 2020;67(8):e28410.
  15. Millen GC, Arnold R, Cazier JB, Curley H, Feltbower RG, Gamble A, et al. Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project. Br J Cancer. 2021;124(4):754-9.
  16. Chan KH, Lee PW, Chan CY, Lam KBH, Ho PL. Monitoring respiratory infections in covid-19 epidemics. BMJ. 2020; doi: 10.1136/bmj.m1628 doi:10.1136/bmj.m1628
  17. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res ClinPract. 2020; doi:10.1016/j.diabres.2020.108347 doi:10.1016/j.diabres.2020.108347
  18. Nassar M, Daoud A, Nso N, Medina L, Ghernautan V, Bhangoo H, et al. Diabetes mellitus and COVID-19: Review article. Diabetes MetabSyndr. 2021;15(6):102268.
  19. Shoaib N, Noureen N, Munir R, Shah FA, Ishtiaq N, Jamil N, et al. COVID-19 severity: Studying the clinical and demographic risk factors for adverse outcomes. PLoS One. 2021;16(8):e0255999.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2022 Journal of Pakistan Society of Internal Medicine.